Anticancer research最新文献

{"title":"Unusual Clinical Presentation of B-Cell Prolymphocytic Leukemia Cases as Splenic Marginal Zone Lymphoma Effectively Treated With Rituximab Monotherapy.","authors":"Sotirios Sachanas, Gerassimos A Pangalis, Maria Moschogiannis, Xanthi Yiakoumis, Christina Kalpadakis, Efstathios Koulieris, Maria K Angelopoulou, Theodoros P Vassilakopoulos","doi":"10.21873/anticanres.17698","DOIUrl":"https://doi.org/10.21873/anticanres.17698","url":null,"abstract":"<p><strong>Background/aim: </strong>B-cell prolymphocytic leukemia (B-PLL) is a rare B-cell neoplasm, historically classified as a distinct entity, but recently removed from the World Health Organization (WHO) classification due to its overlap with other B-cell chronic leukemic lymphoproliferative disorders (B-CLD). We describe five cases that met the classical peripheral blood criteria for B-PLL but exhibited clinicopathological features identical to splenic marginal zone lymphoma (SMZL). This study highlights the diagnostic challenges and treatment outcomes of these cases, emphasizing the need for reconsidering their classification.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed five patients diagnosed with B-PLL between 2008 and 2014. Clinical, hematological, biochemical, morphological, immunophenotypic, immunohistochemical, and molecular characteristics were assessed. Bone marrow aspirates, biopsies, and immunohistochemical staining were performed, and cytogenetic analysis was conducted to identify key molecular markers. All patients received Rituximab monotherapy, following the standard treatment protocol for SMZL.</p><p><strong>Results: </strong>All patients presented with marked prolymphocytosis (>55% circulating lymphoid cells) and massive splenomegaly. Immunophenotypic and bone marrow histologic findings were consistent with SMZL, with a characteristic intrasinusoidal infiltration pattern. Cytogenetic studies revealed the absence of MYC rearrangements and TP53 deletions, with one case exhibiting a 7q31 deletion, a hallmark of SMZL. Rituximab monotherapy was highly effective, leading to complete remission in two patients and prolonged responses in all but one case.</p><p><strong>Conclusion: </strong>These findings suggest that a subset of cases diagnosed as B-PLL based on blood morphology may represent a variant of SMZL with prolymphocytic morphology. The excellent response to Rituximab further supports this hypothesis. Our study reinforces the need for reclassification of such cases within the spectrum of SMZL rather than a separate entity.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3373-3381"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NK Cells Can Target Castration-resistant Prostate Cancer Stem Cells With the Involvement of Degranulation Pathway.","authors":"Asuka Hattori, Taiga Seki, Kazunori Kato, Nantiga Virgona, Yuichi Miyakoshi, Kakeru Kohno, Tomohiro Yano","doi":"10.21873/anticanres.17682","DOIUrl":"https://doi.org/10.21873/anticanres.17682","url":null,"abstract":"<p><strong>Background/aim: </strong>Castration-resistant prostate cancer (CRPC) is lethal and refractory to therapy. To reduce the risk of CRPC, a direct elimination strategy of cancer stem cells is needed, but a promising approach to target cancer stem cells has not yet been established. Natural killer (NK) cells are known to exhibit potent cytotoxic activity against cancer stem cells. In this study, we aimed to clarify whether CRPC cells with stemness characteristics are more sensitive to NK cells than CRPC cells without stemness features.</p><p><strong>Materials and methods: </strong>PC-3 stem-like (PC3-stem) cells separated from the CRPC cell line PC-3 (PC3) using a three-dimensional tumor sphere culture method. Each type of tumor cells (PC3 or PC3-stem) were then co-cultured with the human NK-like cell line KHYG-1, and cell viability was determined using the WST-8 method and crystal violet staining. mRNA levels were determined using real-time PCR, and the expression of each protein was evaluated using flow cytometry and ELISA.</p><p><strong>Results: </strong>KHYG-1 cells exhibited more potent cytotoxicity against PC3-stem cells than PC3 cells. In addition, the mechanism that leads to the NK cell cytotoxicity favoring toward PC3-stem cells was associated with the NKG2D-MICA/B-mediated degranulation pathway.</p><p><strong>Conclusion: </strong>These observations raise the possibility that targeting CRPC stem cells with NK cells may lead to the establishment of novel therapeutic strategies for the suppression of CRPC development.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3197-3207"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of Tumor Immune Microenvironment in Meningiomas: Correlation of Tumor-infiltrating Lymphocyte Aggregates With Tumor Grade.","authors":"Toshiaki Inomo, Masasuke Ohno, Toru Nagasaka, Shunichiro Kuramitsu, Eiji Ito, Tadashi Watanabe, Mitsugu Fujita","doi":"10.21873/anticanres.17710","DOIUrl":"https://doi.org/10.21873/anticanres.17710","url":null,"abstract":"<p><strong>Background/aim: </strong>Malignant meningiomas are aggressive intracranial tumors with high recurrence rates and limited treatment options. The tumor immune microenvironment (TIME) plays a pivotal role in the tumor progression and treatment response. However, its role in meningioma remains largely unknown. This study aimed to analyze tumor-infiltrating lymphocytes (TILs) within the meningioma TIME and investigate their correlation with clinical parameters.</p><p><strong>Patients and methods: </strong>Using tumor specimens from patients diagnosed with meningioma (grade 1, 12 cases; grade 2, 10 cases), the densities of CD4+ T-cells, CD8+ T-cells, CD20+ B-cells, and tissue-resident memory T-cells were quantified using multicolor immunohistochemistry and the QuPath software. The results were analyzed along with clinical parameters, including tumor grades.</p><p><strong>Results: </strong>The density of individual TIL subsets did not correlate with the tumor grades or patients' postoperative neurological function. TIL aggregates were observed in grade 2 meningiomas; clusters of abundant B-cells with a few follicular helper T-cells were observed in one case, indicating the presence of immature tertiary lymphoid structures. A positive correlation was observed between the densities of CD4+ and CD8+ T-cells in grade 2 meningiomas but not in grade 1.</p><p><strong>Conclusion: </strong>The TIME in meningiomas exhibits distinct immune profiles by tumor grade, characterized by the presence of TIL aggregates and coordinated CD4+ and CD8+ T-cell infiltration in higher-grade tumors. These findings may provide insights into the immune landscape of meningiomas and support the development of immunotherapeutic strategies targeting the TIME.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3487-3496"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Evaluation of Immune Cell Therapy in Esophageal Cancer Resistant to Immunochemotherapy.","authors":"Rishu Takimoto, Takashi Kamigaki, Sachiko Okada, Hiroshi Ibe, Eri Oguma, Aya Ohno, Shigenori Goto","doi":"10.21873/anticanres.17716","DOIUrl":"https://doi.org/10.21873/anticanres.17716","url":null,"abstract":"<p><strong>Background/aim: </strong>Immune checkpoint inhibitors (ICIs) have improved cancer therapy outcomes, but effective treatments for ICI-refractory patients remain limited. Our group has investigated αβT cell therapy, which is adoptive immunotherapy, to enhance ICI efficacy. A safety evaluation study conducted in 2017 (UMIN: 000028756) confirmed that αβT cell therapy combined with low-dose ICIs can be administered safely without immune-related adverse events (irAEs). Encouraged by these findings, we launched a clinical trial (jRCTc031190098~031190101) to assess its efficacy. Additionally, a case of renal pelvis cancer achieved complete remission after αβT cell therapy following ICI failure. Given reports showing prolonged PD-1 occupancy post-ICI administration, we hypothesized a similar synergistic effect in ICI-refractory cases.</p><p><strong>Case report: </strong>Esophageal cancer in a 64-year-old woman progressed despite chemoradiation, chemotherapy, and nivolumab, metastasizing to the lymph nodes, lung, and liver. After standard treatment completion, she was referred to our hospital. She developed uveitis as an irAE, which was controlled with steroid drops. In February 2024, three months after nivolumab therapy, αβT cell therapy was initiated (six biweekly doses). No irAEs occurred, and computed tomography (CT) scans showed slight liver metastasis reduction. Flow cytometry revealed increased CD3⁺ and αβT cells, suggesting an enhanced immune response. The MUSCAT assay revealed increased levels of autoantibodies against DDX53, a tumor-associated antigen.</p><p><strong>Conclusion: </strong>αβT cell therapy may enhance the immune response even in ICI-refractory cases. Its safety and potential efficacy warrant further investigation, and a clinical trial (jRCTc030220287) is ongoing to evaluate its role in ICI-refractory cancer.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3553-3559"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Acid Suppressants on Adverse Events of Immune Checkpoint Inhibitors Using Real-world Databases.","authors":"Keisuke Okamoto, Juri Takizawa, Hinata Ueda, Katsuya Narumi, Masaki Kobayashi","doi":"10.21873/anticanres.17689","DOIUrl":"https://doi.org/10.21873/anticanres.17689","url":null,"abstract":"<p><strong>Background/aim: </strong>Immune checkpoint inhibitors (ICIs) cause immune-related adverse events (irAEs) in various organs. Although many studies have suggested that acid suppressants (ASs) may affect irAEs, limited sample sizes have hindered detailed evaluations. Therefore, this study aimed to assess the impact of ASs on individual irAEs using large real-world databases, the Japanese Adverse Drug Event Report database (JADER) and the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).</p><p><strong>Materials and methods: </strong>We analyzed adverse event (AE) reports from the JADER and FAERS databases to assess the impact of ASs on ICI-related AEs. Reporting odds ratios (RORs) and 95% confidence intervals (95%CI) were calculated. Drug-drug interaction signals were defined by non-overlapping 95%CIs between ICIs alone and their combination use.</p><p><strong>Results: </strong>Co-administration with ASs or proton pump inhibitors (PPIs) was associated with an increased risk of acute kidney injury (AKI) in both datasets, while H2-receptor antagonists (H2RAs) showed weaker or no signals. The incidence of endocrine-related AEs tended to decrease with ASs. The colitis results differed between the two datasets, with a decreased incidence in the JADER and an increased incidence in FAERS. Other ICI-related AEs showed consistent trends across datasets. Subgroup analyses of individual PPIs revealed varying results for AKI and colitis between the JADER and FAERS databases, with no consistent trends across PPIs.</p><p><strong>Conclusion: </strong>ASs have diverse effects on ICI-induced AEs and their characteristics may differ between PPIs and H2RAs.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3287-3293"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of SOLIUS UVB Light System in Enhancing Serum 25-Hydroxyvitamin D Concentrations: A Randomized Controlled Trial.","authors":"Arash Shirvani, Michael F Holick","doi":"10.21873/anticanres.17693","DOIUrl":"10.21873/anticanres.17693","url":null,"abstract":"<p><strong>Background/aim: </strong>Vitamin D deficiency is a prevalent global health issue, particularly in regions with limited sunlight exposure. This study aimed to evaluate the efficacy of the SOLIUS system in improving serum 25-hydroxyvitamin D (25(OH)D) concentrations in individuals with vitamin D deficiency or insufficiency, and to assess its safety profile.</p><p><strong>Patients and methods: </strong>This study was conducted with 69 participants, divided into treatment and control groups. The treatment group received ultraviolet B (UVB) exposure from the SOLIUS system, while the control group received sham exposure with blue/purple light. The study included a 5-week titration phase to determine individual UVB sensitivity, followed by a 16-week intervention phase. Serum 25(OH)D concentrations were measured at baseline and at multiple time points using liquid chromatography with tandem mass spectrometry.</p><p><strong>Results: </strong>The treatment group showed a significant increase in serum 25(OH)D concentrations, with an average increase of 10.2 ng/ml from week 1 to week 21 (<i>p</i><0.01), compared to a decrease of 2.3 ng/ml in the control group. Significant predictors of 25(OH)D concentration changes included UV exposure (<i>p</i><0.01) and baseline 25(OH)D concentrations (<i>p</i>=0.01). The SOLIUS system was well-tolerated, with no serious adverse events reported, although 52% of participants experienced minor adverse events such as redness and itchiness.</p><p><strong>Conclusion: </strong>The SOLIUS system effectively increased 25(OH)D concentrations in individuals with vitamin D deficiency or insufficiency, offering a safe solution for improving vitamin D status. These findings have significant implications for public health, particularly for individuals with limited sun exposure or malabsorption issues.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3327-3339"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating the Risk of Radiation Pneumonitis in Elderly Patients With Lung Cancer.","authors":"Dirk Rades, Laura Doehring, Cansu Delikanli, Elisa M Groh, Sabine Bohnet, Stefan Janssen","doi":"10.21873/anticanres.17695","DOIUrl":"https://doi.org/10.21873/anticanres.17695","url":null,"abstract":"<p><strong>Background/aim: </strong>Pneumonitis is a potential complication following radiotherapy of lung cancer, particularly in elderly patients. We developed a risk score for this age group.</p><p><strong>Patients and methods: </strong>Thirteen factors were investigated in 124 elderly lung cancer patients. Factors significantly associated with symptomatic radiation pneumonitis (RP) or showing a trend were used for the score, which was compared to an existing tool created in patients of any age.</p><p><strong>Results: </strong>RP was significantly associated with mean lung dose (MLD). Trends were found for autoimmune disease and cardiovascular disease. Based on these three factors, four risk groups were designed (6-7, 8-9, 11-12, and 14 points). RP rates were 0.0% (0/25), 19.1% (9/47), 51.1% (24/47), and 80.0% (4/5). Positive (PPV) and negative (NPV) predictive values were 80.0% and 100.0%. When using the existing tool based on MLD and autoimmune disease, PPV and NPV were the same.</p><p><strong>Conclusion: </strong>The new score was highly accurate but not superior to the existing tool. The existing tool appears preferable, since it requires only two variables.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3347-3353"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Approach to Minimally Invasive Treatment in Patients With Gastric Cancer Aged Over 80 Years.","authors":"Shota Shimizu, Tomoyuki Matsunaga, Koichiro Kawaguchi, Tomohiro Takahashi, Yukina Yoshida, Yuji Shishido, Kozo Miyatani, Teruhisa Sakamoto, Kazuo Yashima, Hajime Isomoto, Yoshiyuki Fujiwara","doi":"10.21873/anticanres.17699","DOIUrl":"https://doi.org/10.21873/anticanres.17699","url":null,"abstract":"<p><strong>Background/aim: </strong>The number of patients aged ≥80 years with gastric cancer (GC) has recently been increasing. Many have severe comorbidities linked to high mortality after curative surgery. Although minimally invasive surgery is widely performed for GC, elderly patients may benefit from even less invasive, non-standard strategies.</p><p><strong>Patients and methods: </strong>We assessed the treatment outcomes of 122 patients aged ≥80 years who underwent curative gastrectomy at our hospital between 2010-2020.</p><p><strong>Results: </strong>In pStage I, most deaths were from comorbidities, whereas deaths in pStage II/III were both disease-specific and from comorbidities. Multivariate analysis of pStage I variables identified low prognostic nutritional index, open surgery, and American Society of Anesthesiologists physical status classification ≥3 as poor prognostic factors. For pStage II/III, no factors were significantly associated with mortality. Forty-seven out of 69 patients with T1 disease would have been classified as achieving Endoscopic Curability C-2 (eCuraC-2) if endoscopic resection rather than surgery had been performed. The 5-year overall survival rates were similar (58.8% <i>vs.</i> 68.6%, <i>p</i>=0.66) in the 20 patients judged as having eCuraC-2 status after endoscopic resection, with no other additional treatment.</p><p><strong>Conclusion: </strong>Minimally invasive surgery with limited lymph node dissection is preferred for elderly patients with GC with severe comorbidities, including malnutrition, and observation after noncurative endoscopic resection is viable.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3383-3391"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antioxidant Effects of <i>Bidens Pilosa</i> Extract Protect RAW 264.7 Cells from Cisplatin-induced Cytotoxicity.","authors":"Kihiro Shimizu, Ako Kudo, Toko Iida, Keisuke Sato, Akifumi Nakata, Kenichi Komatu, Kazuki Takai, Koji Wakame","doi":"10.21873/anticanres.17707","DOIUrl":"https://doi.org/10.21873/anticanres.17707","url":null,"abstract":"<p><strong>Background/aim: </strong><i>Bidens pilosa</i> (BP) is a medicinal plant that exerts antioxidant and antiallergic effects and is used to treat various diseases. Cisplatin (CDDP) is used for a variety of malignancies, but its use is limited by its side effects. In this study, the effect of BP on reducing CDDP toxicity was examined using RAW264.7 cells, which are normal macrophages.</p><p><strong>Materials and methods: </strong>RAW 264.7 cells were treated with BP and cytotoxicity and antioxidant capacities were measured. RAW 264.7 cells were treated with CDDP with and without BP. The expression of antioxidant-related genes was measured by RT-PCR, whereas apoptosis and reactive oxygen species (ROS) were assessed by flow cytometry.</p><p><strong>Results: </strong>BP inhibited CDDP-induced cytotoxicity in RAW 264.7 cells. Antioxidant gene expression was significantly increased in cells treated with BP and CDDP. BP reduced intracellular ROS as well as the percentage of apoptotic cells in RAW 264.7 cells treated with BP and CDDP.</p><p><strong>Conclusion: </strong>BP reduces CDDP-induced cytotoxicity; these effects are the result of the antioxidant activity of BP.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3459-3467"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Down-regulation of SMPDL3B Inhibits the Proliferation, Migration, and Invasion of Lung Adenocarcinoma Cells.","authors":"Jae Woong Koh, Seon-Joo Park","doi":"10.21873/anticanres.17688","DOIUrl":"https://doi.org/10.21873/anticanres.17688","url":null,"abstract":"<p><strong>Background/aim: </strong>Sphingomyelin phosphodiesterase acid-like 3B (SMPDL3B) is an enzyme involved in lipid metabolism and cellular signaling. SMPDL3B expression is up-regulated in several cancers, suggesting its potential as a novel prognostic biomarker and therapeutic target for cancer treatment. However, its role in lung cancer remains unclear. In this study, we evaluated the biological role of SMPDL3B in lung cancer.</p><p><strong>Materials and methods: </strong>SMPDL3B expression in lung adenocarcinoma (LUAD) tissues and cells was validated using quantitative real-time PCR and western blotting. To determine the role of SMPDL3B in LUAD cells, a small interfering RNA targeting SMPDL3B was used to suppress intracellular gene expression. Cell proliferation was performed using MTT and colony formation assays, and transwell assays with or without Matrigel were used to evaluate the role of SMPDL3B in LUAD cells migration and invasion.</p><p><strong>Results: </strong>SMPDL3B was overexpressed in LUAD tissues and cells. Knockdown of SMPLD3B significantly inhibited cell proliferation by regulating cell cycle progression and also prevented the migration and invasion of LUAD cells.</p><p><strong>Conclusion: </strong>SMPDL3B plays a role in LUAD, suggesting its potential as a therapeutic target for selective and personalized lung cancer treatment.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3275-3286"},"PeriodicalIF":1.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}